New Launch19 March 2026 at 03:06 am
Glenmark Therapeutics Inc., USA Launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) in the U.S.
AI Summary
Glenmark Pharmaceuticals Limited has received final approval by the U.S. FDA for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). The product is bioequivalent to the reference listed drug, Flonase® Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC. The product will be distributed in the U.S. by Glenmark Therapeutics Inc., USA and is expected to launch in April 2026. The Flonase® Allergy Relief Nasal Spray market achieved annual sales of approximately $384.7 million as per Nielsen® syndicated data for the latest 52-week period ending March 3, 2026.
Key Highlights
- Glenmark Pharmaceuticals Limited receives final approval from the U.S. FDA for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC).
- The product is bioequivalent to the reference listed drug, Flonase® Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC.
- Glenmark Therapeutics Inc., USA to distribute the product in the U.S.
- The product is expected to launch in April 2026.
- The Flonase® Allergy Relief Nasal Spray market achieved annual sales of approximately $384.7 million as per Nielsen® syndicated data.